Download MendeleyDesign of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Freeman, G.A., Andrews Iii, C.W., Hopkins, A.L., Lowell, G.S., Schaller, L.T., Cowan, J.R., Gonzales, S.S., Koszalka, G.W., Hazen, R.J., Boone, L.R., Ferris, R.G., Creech, K.L., Roberts, G.B., Short, S.A., Weaver, K., Reynolds, D.J., Milton, J., Ren, J., Stuart, D.I., Stammers, D.K., Chan, J.H.(2004) J Med Chem 47: 5923-5936
- PubMed: 15537347 Search on PubMed
- DOI: https://doi.org/10.1021/jm040072r
- Primary Citation of Related Structures:
1TKX - PubMed Abstract:
- Crystal Structures of HIV-1 Reverse Transcriptases at Codons 100, 106 and 108 and Mechanisms of Resist Non-Nucleoside Inhibitors
Ren, J., Nichols, C.E., Chamberlain, P.P., Weaver, K.L., Short, S.A., Stammers, D.K.
(2004) J Mol Biol 336: 569 - Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215
Chamberlain, P.P., Ren, J., Nichols, C.E., Douglas, L., Lennerstrand, J., Larder, B.A., Stuart, D.I., Stammers, D.K.
(2002) J Virol 76: 10015 - Structural Mechanisms of Drug Resistance for Mutations at Codons 181 and 188 in HIV-1 Reverse Transcriptase and the Improved Resilience of Second Generation Non-Nucleoside Inhibitors
Ren, J., Nichols, C., Bird, L., Chamberlain, P., Weaver, K.L., Short, S.A., Stuart, D.I., Stammers, D.K.
(2001) J Mol Biol 312: 795 - 2-Amino-6-Arylsulfonylbenzonitriles as Non-Nucleosi Transcriptase Inhibitors of HIV-1
Chan, J.H., Hong, J.S., Hunter III, R.N., Orr, G.F., Cowan, J.R., Sherman, D.B., Sparks, S.M., Reitter, B.E., Hazen, C.W., Andrews III, R.J., St Clair, M., Boone, L.R., Ferris, R.G., Roberts, K.L., Cree, G.B., Short, S.A., Weaver, K., Ott, R.J., Ren, J., Hopkins, A., Stuart, D.I., Stammers, D.K.
(2001) J Med Chem 44: 1866 - Structural Basis for the Resilience of Efavirenz (Dmp-266) to Drug Resistant Mutations in HIV-1 Reverse Transcriptase
Ren, J., Milton, J., Weaver, K.L., Short, S.A., Stuart, D.I., Stammers, D.K.
(2000) Structure 8: 1089 - Binding of the Second Generattion Non-Nucleoside Inhibitor S-1153 to HIV-1 Reverse Transcriptase Involves Extensive Main Chain Hydrogen Bonding
Ren, J., Nichols, C., Bird, L.E., Fujiwara, T., Suginoto, H., Stuart, D.I., Stammers, D.K.
(2000) J Biol Chem 275: 14316 - Phenethylthiazolylthiourea (Pett) Non-Nucleoside Inhibitors of HIV-1 and HIV-2 Reverse Transcriptases: Structural and Biochemical Analyses
Ren, J., Diprose, J., Warren, J., Esnouf, R.M., Bird, L.E., Ikemizu, S., Slater, M., Milton, J., Balzarini, J., Stuart, D.I., Stammers, D.K.
(2000) J Biol Chem 275: 5633 - Crystallographic Analysis of the Binding Modes of Non-Nucleoside Thiazoloisoindolinone Inhibitors to HIV-1 Reverse Transcriptase and Comparison with Modeling Studies
Ren, J., Esnouf, R.M., Hopkins, A.L., Stuart, D.I., Stammers, D.K.
(1999) J Med Chem 42: 3845 - Design of Mkc-442 (Emivirine) Analogues with Improved Activity Against Drug-Resistant HIV Mutants
Hopkins, A.L., Ren, J., Tanaka, H., Baba, M., Okamato, M., Stuart, D.I., Stammers, D.K.
(1999) J Med Chem 42: 4500 - Crystal Structures of Reverse Transcriptase in Complex with Carboxanilide Derivatives
Ren, J., Esnouf, R.M., Hopkins, A.L., Warren, J., Balzarini, J., Stuart, D.I., Stammers, D.K.
(1998) Biochemistry 37: 14394 - 3'-Azido-3'-Deoxythymidine Drug Resistance Mutations in HIV-1 Reverse Transcriptase Can Induce Long Range Conformational Changes
Ren, J., Esnouf, R.M., Hopkins, A.L., Jones, E.Y., Kirby, I., Keeling, J., Ross, C.K., Larder, B.A., Stuart, D.I., Stammers, D.K.
(1998) Proc Natl Acad Sci U S A 95: 9518 - Continuous and Discontinuous Changes in the Unit Cell of HIV-1 Reverse Transcriptase Crystals on Dehydration
Esnouf, R.M., Ren, J., Garman, E., Somers, D.O., Ross, C.K., Jones, E.Y., Stammers, D.K., Stuart, D.I.
(1998) Acta Crystallogr D Biol Crystallogr 54: 938 - Unique Features in the Structure of the Complex between HIV-1 Reverse Transcriptase and the Bis(Heteroaryl)Piperazine (Bhap) U-90152 Explain Resistance Mutations for This Non-Nucleoside Inhibitor
Esnouf, R.M., Ren, J., Hopkins, A.L., Ross, C.K., Jones, E.Y., Stammers, D.K., Stuart, D.I.
(1997) Proc Natl Acad Sci U S A 94: 3984 - Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors
L Hopkins, A., Ren, J., Esnouf, R.M., Willcox, B.E., Jones, E.Y., Ross, C.K., Miyasaka, T., Walker, R.T., Tanaka, H., Stammers, D.K., Stuart, D.I.
(1996) J Med Chem 39: 1589 - The Structure of HIV-1 Reverse Transcriptase Complexed with 9-Chloro-TIBO: Lessons for Inhibitor Design
Ren, J., Esnouf, R.M., Hopkins, A.L., Ross, C.K., Jones, E.Y., Stammers, D.K., Stuart, D.I.
(1995) Structure 3: 915 - High Resolution Structures of HIV-1 RT from Four RT-Inhibitor Complexes
Ren, J., Esnouf, R.M., Garman, E., Somers, D.O., Ross, C.K., Kirby, I., Keeling, J., Darby, G., Jones, E.Y., Stuart, D.I., Stammers, D.K.
(1995) Nat Struct Biol 2: 293 - Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Non-Nucleoside Inhibitors
Esnouf, R.M., Ren, J., Ross, C.K., Jones, E.Y., Stammers, D.K., Stuart, D.I.
(1995) Nat Struct Biol 2: 303 - Crystals of HIV-1 Reverse Transcriptase Diffracting to 2.2 Angstrom Resolution
Stammers, D.K., Somers, D.O., Ross, C.K., Kirby, I., Ray, P.H., Wilson, J.E., Norman, M., Ren, J., Esnouf, R.M., Garman, E., Jones, E.Y., Stuart, D.I.
(1994) J Mol Biol 242: 586
HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV treatment must include selective potent activity against both wild-type virus as well as against mutant virus that have been selected by use of current antiretroviral treatment regimens ...
HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) are part of the combination therapy currently used to treat HIV infection. The features of a new NNRTI drug for HIV treatment must include selective potent activity against both wild-type virus as well as against mutant virus that have been selected by use of current antiretroviral treatment regimens. Based on analogy with known HIV-1 NNRTI inhibitors and modeling studies utilizing the X-ray crystal structure of inhibitors bound in the HIV-1 RT, a series of substituted 2-quinolones was synthesized and evaluated as HIV-1 inhibitors.
Related Citations:
Organizational Affiliation:
GlaxoSmithKline Research and Development, 5 Moore Drive, Research Triangle Park, North Carolina 27709, USA. Andy.A.Freeman@gsk.com
